Pharmacological agents like the dynein‐antagonist LDC‐3/Dynarrestin, metformin, and sulforaphane, which modulate ER‐mitochondria contacts by regulating MAM‐tethering proteins, are currently undergoing preclinical and clinical trials for cancer and metabolic disorders.26, 78, 79, 80, 81, 82, 83. The gene discussed is SGCG; the disease is metabolic disease.